AASLD/EASL 2014 GUIDELINE OVERVIEW

Quickly review the recommended options for adult patients with overt hepatic encephalopathy (HE).

Download the Guidelines Overview
 
Image show an HE Symptoms Checklist

HE symptom checklist

Help your patients and their caregivers identify the signs of an HE episode by giving them the easy-to-use HE Symptom Checklist. It’s a handy tool that can help them recognize the mental and physical symptoms of HE and alert you before their condition worsens.

The HE Symptom Checklist is also available to patients and caregivers on the XIFAXAN patient website.

Download HE Symptom Checklist
 

XIF.0188.USA.18

HE HOSPITAL DISCHARGE GUIDE

Ease the transition to everyday life for your patients hospitalized for overt HE. This guide offers information about HE they should know before and after discharge from the hospital.

The HE Hospital Discharge Guide is also available to patients and caregivers on the XIFAXAN patient website.

Download HE Hospital Discharge Guide
 
H.E.L.P. Support Guide FOR PATIENTS

H.E.L.P. Support Guide FOR PATIENTS

If you have prescribed XIFAXAN for the ongoing management of overt HE, your patients may have questions. Download this guide to help them find answers and details on the HE Living Program (H.E.L.P.) text message support that is available.

Signing up is quick and easy—instruct patients or caregivers to text REDUCE to 90803 to get started* or click the download for more information.
Habla español? Envíe REDUCIR al 90803 para registrarse.

Download the H.E.L.P. Support Guide

*At no cost with an unlimited texting plan; otherwise, message & data rates may apply. Message frequency determined by user. Text HELP to 90803 for help. Text STOP to 90803 to cancel at any time. For terms, visit cs1.me/heliving

 
Image shows an icon of a man figure infront of a chart board - for requesting a representative.

REQUEST A REPRESENTATIVE VISIT

A representative can visit your practice to answer any questions about XIFAXAN, as well as deliver samples and patient support materials.

Request A Representative Visit
XIF.0051.USA.18
 
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.